Safety review for Maxipime

THE Food and Drug Administration is examining safety data on Maxipime, also available in generic form as cefepime, after an article in the journal Lancet raised the possibility that the medicine increased the risk of death, the agency said in an “early communication” on its website.

Elan announced plans to reduce spending by $40 million (€27.24m) a year to make up for lost revenue after a generic version of Maxipime won US approval on June 18, earlier than the company expected.